Member Info for JayMonk

someone buying in the back ground.

Looking good for a strong close.

the placing will be at ? The Company also announces that subject to shareholder approval it is considering an issue of new Ordinary Shares by way of a placing to raise up to £2.0 million, the proceeds of which will be used to repay the Company's current indebtedness and for working capital purposes. In particular, the proceeds will be used to fund the development of the Company's Events business, including the successful 'Woman in.." series as well as expanding the capabilities of the Company's exisiting digital platforms and to fund new business development. The new business areas will concentrate on the provision of media and equity research for both institutional and private investors. The Company has been informed that Messrs Stilwell and Cross intend in aggregate to invest £0.5 million in the proposed fund raising. A further announcement will be made in due course.

me to

Good sign :-)

Just look at the Major shareholders, all experts in there field, and options at 10p 20p 50p plenty of news to come. Major Shareholders Woodford Investment Managers 401,597,920 33.31% Mr R Griffiths 173,071,097 14.35% David Norwood 105,938,633 8.79% Marcelo Bravo 65,000,000 5.39% Southern Fox Investments Ltd 51,000,000 4.23% Henderson Global Investors 49,400,000 4.10% Octopus Investments 42,140,345 3.50% Aviva Investors 37,964,329 3.15% Mr R Quested 37,247,753 3.09% Highlights Substantive progress in commercialisation discussions regarding the Company’s lead NSAID1 assets, OXPzeroTM Ibuprofen and OXPzeroTM Naproxen Feedback has identified the key precursors to successful partnership outcomes, including: additional platform development clarity on regulatory pathway for over the counter (OTC) and Prescription (Rx) product approval Significant progress advancing the OXPzeroTM technology platform: Improvement of drug release in vitro Scale-up and optimisation of the manufacturing process Strengthening of the intellectual property (IP) portfolio Planning to conduct small-scale exploratory pharmacokinetic (PK) trials to validate the in vivo performance of formulation improvements, with details to be announced separately in due course Ongoing dialogue including the initiation of broader outreach to include the Rx market Proceeding to seek pre-IND meetings with the US FDA to clarify US regulatory pathway License per product would mean £20-30m upfront payment, Further sales milestone payments and mid teen royalty payments, Gastric safe NSAID’s potential sales of over £500m

Substantive progress in commercialisation discussions regarding the Company’s lead NSAID1 assets, OXPzeroTM Ibuprofen and OXPzeroTM Naproxen Feedback has identified the key precursors to successful partnership outcomes, including: additional platform development clarity on regulatory pathway for over the counter (OTC) and Prescription (Rx) product approval Significant progress advancing the OXPzeroTM technology platform: Improvement of drug release in vitro Scale-up and optimisation of the manufacturing process Strengthening of the intellectual property (IP) portfolio Planning to conduct small-scale exploratory pharmacokinetic (PK) trials to validate the in vivo performance of formulation improvements, with details to be announced separately in due course Ongoing dialogue including the initiation of broader outreach to include the Rx market Proceeding to seek pre-IND meetings with the US FDA to clarify US regulatory pathway License per product would mean £20-30m upfront payment, Further sales milestone payments and mid teen royalty payments, Gastric safe NSAID’s potential sales of over £500m

bid has increased :-0

in the morning so far, has always been followed buy a rise and strong finish, L2 looking good, watch out for the delayed buy.

NSAIDs $12bn worldwide sales. Statins $20bn worldwide sales.

yeah, nice drop to fill the order :-)

Highlights Substantive progress in commercialisation discussions regarding the Company's lead NSAID1 assets, OXPzeroTM Ibuprofen and OXPzeroTM Naproxen Feedback has identified the key precursors to successful partnership outcomes, including: additional platform development clarity on regulatory pathway for over the counter (OTC) and Prescription (Rx) product approval Significant progress advancing the OXPzeroTM technology platform: Improvement of drug release in vitro Scale-up and optimisation of the manufacturing process Strengthening of the intellectual property (IP) portfolio Planning to conduct small-scale exploratory pharmacokinetic (PK) trials to validate the in vivo performance of formulation improvements, with details to be announced separately in due course Ongoing dialogue including the initiation of broader outreach to include the Rx market Proceeding to seek pre-IND meetings with the US FDA to clarify US regulatory pathway License per product would mean £20-30m upfront payment, Further sales milestone payments and mid teen royalty payments, Gastric safe NSAID's potential sales of over £500m Marcelo Bravo, Chief Executive Officer, commented We are very encouraged with the strong traction we are getting from some of the major potential partners in our discussions and we are also continuing to progress our other pipeline opportunities including Asprin and statins Ibuprofen is currently the dominant NSAID molecule in the pain relief and anti-inflammatory sector with worldwide sales of Ibuprofen in excess of $5bn per annum. The Company has initiated contact with a number of large, global pharmaceutical companies with strategic interest in the ibuprofen market and is at an advanced stage of preparing information to proceed to the commercialisation phase with the OXPzeroTM Ibuprofen asset.

options at 10p 20p 50p Well worth a view, for those who have not seen it yet. https://www.youtube.com/watch?v=79BLamZ9NEg

good indication that the seller has cleared,

Highlights Substantive progress in commercialisation discussions regarding the Company's lead NSAID1 assets, OXPzeroTM Ibuprofen and OXPzeroTM Naproxen Feedback has identified the key precursors to successful partnership outcomes, including: additional platform development clarity on regulatory pathway for over the counter (OTC) and Prescription (Rx) product approval Significant progress advancing the OXPzeroTM technology platform: Improvement of drug release in vitro Scale-up and optimisation of the manufacturing process Strengthening of the intellectual property (IP) portfolio Planning to conduct small-scale exploratory pharmacokinetic (PK) trials to validate the in vivo performance of formulation improvements, with details to be announced separately in due course Ongoing dialogue including the initiation of broader outreach to include the Rx market Proceeding to seek pre-IND meetings with the US FDA to clarify US regulatory pathway License per product would mean £20-30m upfront payment, Further sales milestone payments and mid teen royalty payments, Gastric safe NSAID's potential sales of over £500m Marcelo Bravo, Chief Executive Officer, commented We are very encouraged with the strong traction we are getting from some of the major potential partners in our discussions and we are also continuing to progress our other pipeline opportunities including Asprin and statins Ibuprofen is currently the dominant NSAID molecule in the pain relief and anti-inflammatory sector with worldwide sales of Ibuprofen in excess of $5bn per annum. The Company has initiated contact with a number of large, global pharmaceutical companies with strategic interest in the ibuprofen market and is at an advanced stage of preparing information to proceed to the commercialisation phase with the OXPzeroTM Ibuprofen asset.

shares bought in to close, not worried about the seller, as there are plenty of big buyers eating them up at the full ask.

buying in to close :-)

yep, bid has just increased, so looks like someone is fishing for shares.

delayed buy :-)

https://www.britishbulls.com/m/SignalPage.aspx?lang=en&Ticker=OXP.L